Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Chemomab Therapeutics Ltd DRC

Healthcare US CMMB

1.5196USD
0.0096(0.64%)

Last update at 2026-06-23T15:00:00Z

Day Range

1.501.60
LowHigh

52 Week Range

1.355.88
LowHigh

Fundamentals

  • Previous Close 1.51
  • Market Cap11.95M
  • Volume31845
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.49700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -9.06636M -13.94500M -24.22100M -28.18000M -12.47800M
Minority interest - - - - -
Net income -9.06636M -13.94500M -24.22100M -27.64600M -12.55500M
Selling general administrative 3.73M 0.00341M 7.08M 11.56M 6.03M
Selling and marketing expenses - - 7.05M - -
Gross profit -0.07056M -0.05325M -0.06683M - -
Reconciled depreciation 0.07M 0.05M 0.07M 0.06M 0.03M
Ebit -9.64289M -14.01118M -25.45900M -28.53300M -12.40100M
Ebitda -9.57234M -13.95793M -25.39200M -28.47500M -12.36700M
Depreciation and amortization 0.07M 0.05M 0.07M 0.06M 0.03M
Non operating income net other - - - - -
Operating income -9.64289M -14.73900M -25.45900M -28.53300M -12.40100M
Other operating expenses 9.64M 14.74M 25.46M 28.53M 12.37M
Interest expense - - - 0.35M 0.11M
Tax provision 0.00000M 0.00000M 0.00000M -0.53400M -
Interest income 0.57M 0.79M 1.24M - -
Net interest income 0.57M 0.79M 1.24M 0.35M -0.11100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M -0.53400M 0.08M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 9.57M 14.74M 25.46M 28.53M 12.37M
Cost of revenue 0.07M 0.05M 0.07M - -
Total other income expense net 0.58M 0.79M 1.24M 0.35M -0.07700M
Discontinued operations - - - - -
Net income from continuing ops -8.99500M -13.94500M -24.22100M -27.64600M -12.47800M
Net income applicable to common shares - - - -27.64600M -12.47800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13.81M 16.96M 22.15M 43.06M 64.35M
Intangible assets 0.01M 0.00662M - - -
Earning assets - - - - -
Other current assets - 1.51M 1.04M 1.38M 47.50M
Total liab 1.48M 3.43M 5.15M 6.84M 2.89M
Total stockholder equity 12.33M 13.54M 17.00M 36.22M 61.47M
Deferred long term liab - - - - -
Other current liab 0.99M 2.44M 4.25M 4.94M 1.21M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -111.61627M -102.62300M -88.67853M -63.81900M -36.17300M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.73M 0.96M
Cash 7.56M 6.07M 9.37M 13.52M 14.69M
Cash and equivalents - - - - -
Total current liabilities 1.48M 3.22M 4.84M 6.75M 2.65M
Current deferred revenue - - - - -
Net debt -7.56388M -5.74700M -8.97605M -13.30500M -14.34300M
Short term debt - 0.12M 0.08M 0.12M 0.11M
Short long term debt - - - - -
Short long term debt total - 0.32M 0.39M 0.21M 0.34M
Other stockholder equity 123.95M 116.16M 105.68M 100.04M 97.64M
Property plant equipment - - - 0.59M 0.70M
Total current assets 13.42M 16.04M 20.90M 41.74M 62.69M
Long term investments - - - - 0.00000M
Net tangible assets - - - 36.22M 61.47M
Short term investments 2.80M 8.20M 10.49M 26.37M 46.48M
Net receivables 3.06M 0.26M 0.29M 0.46M 1.53M
Long term debt - - - - -
Inventory - 0.00000M -1.03700M - -47.50200M
Accounts payable 0.48M 0.67M 0.52M 1.69M 1.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.21M 0.38M 0.56M 0.73M 0.96M
Deferred long term asset charges - - - - -
Non current assets total 0.39M 0.92M 1.25M 1.33M 1.67M
Capital lease obligations 0.00000M 0.32M 0.39M 0.21M 0.34M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 2.30M 15.88M 19.53M -45.18600M
Change to liabilities - - - 0.35M 1.18M
Total cashflows from investing activities 5.43M - - 19.53M -45.18600M
Net borrowings - - - - -
Total cash from financing activities 7.21M 9.87M 3.50M -0.80800M 61.07M
Change to operating activities - - - 3.72M -1.06600M
Net income -9.06636M -13.94500M -24.22100M -27.64600M -12.47800M
Change in cash 1.42M -3.22100M -4.22800M -1.64500M 3.51M
Begin period cash flow 6.15M 9.37M 13.60M 15.24M 11.73M
End period cash flow 7.56M 6.15M 9.37M 13.60M 15.24M
Total cash from operating activities -11.21829M -15.38600M -23.61100M -20.37000M -12.37400M
Issuance of capital stock 7.14M 9.87M 3.50M 0.27M 58.64M
Depreciation 0.07M 0.05M 0.07M 0.06M 0.03M
Other cashflows from investing activities - 2.30M 15.88M 19.60M 1.00M
Dividends paid - - - - -
Change to inventory - - -0.00090M 0.00006M 0.00206M
Change to account receivables - - 0.00090M -0.00006M -0.00206M
Sale purchase of stock - 0.00000M 0.00000M -1.21800M 0.00000M
Other cashflows from financing activities - - 15.88M 0.14M 2.44M
Change to netincome - - - 3.21M 2.02M
Capital expenditures 0.00303M 0.00000M 0.00300M 0.07M 0.24M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.85749M -2.11100M -0.94556M 4.01M -1.94900M
Stock based compensation 0.62M 0.62M 1.49M 3.21M 2.02M
Other non cash items 0.63M 0.67M -0.00227M 2.96M 0.91M
Free cash flow -11.22132M -15.38600M -23.61400M -20.43800M -12.61300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CMMB
Chemomab Therapeutics Ltd DRC		 0.0096 0.64% 1.52 - 12.94 - 0.99 0.33
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Chemomab Therapeutics Ltd DRC

Building C, Tel Aviv-Yafo, Israel, 6158101

Key Executives

Name Title Year Born
Dr. Dale R. Pfost Ph.D. Chairman & CEO 1957
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer & Exec. Director 1982
Mr. Donald R. Marvin MBA CFO, Exec. VP & COO 1953
Barbara Lindheim Consulting VP of Investor & PR, Strategic Communications NA
Mr. Mitchell Lawrence Jones M.D., Ph.D. VP of Corp. Devel. & Strategy NA
Dr. Matthew Frankel M.B.A., M.D. Chief Medical Officer & VP of Drug Devel. NA
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, CEO & Executive Director 1982
Ms. Sigal Fattal CPA, M.B.A. Chief Financial Officer 1971
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer & VP of Drug Development 1969
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.